Cited by 2,098SARS-CoV-2 and COVID-19 ResearchAnimal Virus Infections Studiesvaccines and immunoinformatics approaches

The DOI matches its Crossref record; 114 of the 114 references it cites were found in a registry or an index.

SARS-CoV-2 vaccines in development

Open access

Krammer, Florian·2020·Nature

Open this paper in CoChat — free account

Abstract

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was first reported in late 2019 in China and is the causative agent of the coronavirus disease 2019 (COVID-19) pandemic. To mitigate the effects of the virus on public health, the economy and society, a vaccine is urgently needed. Here I review the development of vaccines against SARS-CoV-2. Development was initiated when the genetic sequence of the virus became available in early January 2020, and has moved at an unprecedented speed: a phase I trial started in March 2020 and there are currently more than 180 vaccines at various stages of development. Data from phase I and phase II trials are already available for several vaccine candidates, and many have moved into phase III trials. The data available so far suggest that effective and safe vaccines might become available within months, rather than years.

Integrity signals

Registry

Crossref · 10.1038/s41586-020-2798-3

Cites

114 of 114 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

A novel coronavirus from patients with pneumonia in China, 2019
Zhu, N., Zhang, D., Wang, W., Li, X., Yang, B., Song, J., Zhao, X., Huang, B., Shi, W., Lu, R., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2001017 · Cited by 28,244
A pneumonia outbreak associated with a new coronavirus of probable bat origin
Zhou, P., Yang, X.-L., Wang, X.-G., Hu, B., Zhang, L., Zhang, W., Si, H.-R., Zhu, Y., Li, B., Huang, C.-L., et al. (2020) · Nature · doi:10.1038/s41586-020-2012-7 · Cited by 21,969
Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation
Wrapp, D., Wang, N., Corbett, K. S., Goldsmith, J. A., Hsieh, C.-L., Abiona, O., Graham, B. S., & McLellan, J. S. (2020) · Science · doi:10.1126/science.abb2507 · Cited by 8,897
Origin and evolution of pathogenic coronaviruses
Cui, J., Li, F., & Shi, Z. (2018) · Nature Reviews Microbiology · doi:10.1038/s41579-018-0118-9 · Cited by 5,729
Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals
Grifoni, A., Weiskopf, D., Ramirez, S. I., Mateus, J., Dan, J. M., Moderbacher, C. R., Rawlings, S. A., Sutherland, A., Premkumar, L., Jadi, R. S., et al. (2020) · Cell · doi:10.1016/j.cell.2020.05.015 · Cited by 3,595
Self-citation
An mRNA Vaccine against SARS-CoV-2 — Preliminary Report
Jackson, L. A., Anderson, E. J., Rouphael, N. G., Roberts, P. C., Makhene, M., Coler, R. N., McCullough, M. P., Chappell, J. D., Denison, M. R., Stevens, L. J., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2022483 · Cited by 3,237
Functional assessment of cell entry and receptor usage for SARS-CoV-2 and other lineage B betacoronaviruses
Letko, M., Marzi, A., & Munster, V. (2020) · Nature Microbiology · doi:10.1038/s41564-020-0688-y · Cited by 3,109
RNA-Based COVID-19 Vaccine BNT162b2 Selected for a Pivotal Efficacy Study
Walsh, E. E., Frenck, R., Falsey, A. R., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Neuzil, K., Mulligan, M. J., Bailey, R., et al. (2020) · doi:10.1101/2020.08.17.20176651 · Cited by 2,615
Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial
Folegatti, P. M., Ewer, K. J., Aley, P. K., Angus, B., Becker, S., Belij-Rammerstorfer, S., Bellamy, D., Bibi, S., Bittaye, M., Clutterbuck, E. A., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)31604-4 · Cited by 2,419
Susceptibility of ferrets, cats, dogs, and other domesticated animals to SARS–coronavirus 2
Shi, J., Wen, Z., Zhong, G., Yang, H., Wang, C., Huang, B., Liu, R., He, X., Shuai, L., Sun, Z., et al. (2020) · Science · doi:10.1126/science.abb7015 · Cited by 1,952

Show all 101 references

Research works printed but not linked: 1

The National Academies of Sciences, Engineering and Medicine. Discussion Draft of the Preliminary Framework for Equitable Allocation of COVID-19 Vaccine (The National Academies Press, 2020).

Sorted by citations

Items 101–200 of 1,004

Investigating COVID-19 News Across Four Nations: A Topic Modeling and Sentiment Analysis Approach
Ghasiya, P., & Okamura, K. (2021) · IEEE Access · doi:10.1109/access.2021.3062875 · Cited by 143
Fast-spreading SARS-CoV-2 variants: challenges to and new design strategies of COVID-19 vaccines
Zhou, W., & Wang, W. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00644-x · Cited by 134
SARS-CoV-2 Nsp5 Demonstrates Two Distinct Mechanisms Targeting RIG-I and MAVS To Evade the Innate Immune Response
Liu, Y., Qin, C., Rao, Y., Ngo, C., Feng, J. J., Zhao, J., Zhang, S. J., Wang, T., Carrière, J., Savas, A. C., et al. (2021) · mBio · doi:10.1128/mbio.02335-21 · Cited by 135
Dissolvable polymer microneedles for drug delivery and diagnostics
Ali, M., Namjoshi, S., Benson, H. A., Mohammed, Y., & Kumeria, T. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.04.043 · Cited by 130
Antibody Responses to SARS-CoV-2 mRNA Vaccines Are Detectable in Saliva
Ketas, T. J., Chaturbhuj, D. N., Portillo, V. M. C., Francomano, E., Golden, E. B., Chandrasekhar, S., Debnath, G., Diaz-Tapia, R., Yasmeen, A., Kramer, K. D., et al. (2021) · Pathogens and Immunity · doi:10.20411/pai.v6i1.441 · Cited by 126
The impact of spike mutated variants of SARS-CoV2 [Alpha, Beta, Gamma, Delta, and Lambda] on the efficacy of subunit recombinant vaccines
Mohammadi, M., Shayestehpour, M., & Mirzaei, H. (2021) · The Brazilian Journal of Infectious Diseases · doi:10.1016/j.bjid.2021.101606 · Cited by 142
Immunological memory to SARS-CoV-2 assessed for up to eight months after infectionPreprint
Dan, J., Mateus, J., Kato, Y., Hastie, K., Yu, E., Faliti, C. E., Grifoni, A., Ramirez, S., Haupt, S., Frazier, A., et al. (2020) · bioRxiv · doi:10.1101/2020.11.15.383323 · Cited by 147
Self-citation
Count on us: T cells in SARS-CoV-2 infection and vaccination
Kedzierska, K., & Thomas, P. G. (2022) · Cell Reports Medicine · doi:10.1016/j.xcrm.2022.100562 · Cited by 124
COVID-19 vaccines for patients with cancer: benefits likely outweigh risks
Hwang, J. K., Zhang, T., Wang, A. Z., & Li, Z. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-021-01046-w · Cited by 127
Determinants of COVID-19 Vaccine Acceptance among the Adult Population of Bangladesh Using the Health Belief Model and the Theory of Planned Behavior Model
Patwary, M. M., Bardhan, M., Disha, A. S., Hasan, M., Haque, M. Z., Sultana, R., Hossain, M. R., Browning, M. H. E. M., Alam, M. A., & Sallam, M. (2021) · Vaccines · doi:10.3390/vaccines9121393 · Cited by 128
Distinct Features and Functions of Systemic and Mucosal Humoral Immunity Among SARS-CoV-2 Convalescent Individuals
Butler, S. E., Crowley, A. R., Natarajan, H., Xu, S., Weiner, J. A., Bobak, C. A., Mattox, D. E., Lee, J., Wieland‐Alter, W., Connor, R. I., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2020.618685 · Cited by 120
Silencing of SARS‐CoV‐2 with modified siRNA‐peptide dendrimer formulation
Khaitov, M. R., Nikonova, A. A., Shilovskiy, I. P., Kozhikhova, K. V., Кофиади, И. А., Vishniakova, L. I., Nikolskii, A., Gattinger, P., Kovchina, V. I., Barvinskaia, E. D., et al. (2021) · Allergy · doi:10.1111/all.14850 · Cited by 123
Emerging SARS-CoV-2 Variants of Concern (VOCs): An Impending Global Crisis
Thye, A. Y.-K., Law, J. W., Pusparajah, P., Letchumanan, V., Chan, K., & Lee, L. (2021) · Biomedicines · doi:10.3390/biomedicines9101303 · Cited by 121
Single-component, self-assembling, protein nanoparticles presenting the receptor binding domain and stabilized spike as SARS-CoV-2 vaccine candidates
He, L., Lin, X., Wang, Y., Abraham, C., Sou, C., Ngo, T., Zhang, Y., Wilson, I. A., & Zhu, J. (2021) · Science Advances · doi:10.1126/sciadv.abf1591 · Cited by 121
Cryo-EM structure of a SARS-CoV-2 omicron spike protein ectodomain
Ye, G., Liu, B., & Li, F. (2022) · Nature Communications · doi:10.1038/s41467-022-28882-9 · Cited by 121
Comparing infectivity and virulence of emerging SARS-CoV-2 variants in Syrian hamsters
Abdelnabi, R., Boudewijns, R., Foo, C. S.-Y., Seldeslachts, L., Sánchez-Felipe, L., Zhang, X., Delang, L., Maes, P., Kaptein, S. J. F., Weynand, B., et al. (2021) · EBioMedicine · doi:10.1016/j.ebiom.2021.103403 · Cited by 103
Evolution of SARS-CoV-2 Variants: Implications on Immune Escape, Vaccination, Therapeutic and Diagnostic Strategies
Zabidi, N. Z., Liew, H. L., Farouk, I. A., Puniyamurti, A., Yip, A. J. W., Wijesinghe, V. N., Low, Z. Y., Tang, J. W.-T., Chow, V. T. K., & Lal, S. K. (2023) · Viruses · doi:10.3390/v15040944 · Cited by 129
Clinical approval of nanotechnology-based SARS-CoV-2 mRNA vaccines: impact on translational nanomedicine
Milane, L. S., & Amiji, M. M. (2021) · Drug Delivery and Translational Research · doi:10.1007/s13346-021-00911-y · Cited by 119
Nasal vaccination against SARS-CoV-2: Synergistic or alternative to intramuscular vaccines?
Tiboni, M., Casettari, L., & Illum, L. (2021) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2021.120686 · Cited by 116
Advances in intranasal vaccine delivery: A promising non-invasive route of immunization
Kehagia, E., Papakyriakopoulou, P., & Valsami, G. N. (2023) · Vaccine · doi:10.1016/j.vaccine.2023.05.011 · Cited by 121
Humoral immune responses and neutralizing antibodies against SARS-CoV-2; implications in pathogenesis and protective immunity
Carrillo, J., Izquierdo‐Useros, N., Ávila‐Nieto, C., Pradenas, E., Clotet, B., & Blanco, J. (2020) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2020.10.108 · Cited by 120
Mutations of SARS-CoV-2 spike protein: Implications on immune evasion and vaccine-induced immunity
Mengist, H. M., Kombe, A. J. K., Mekonnen, D. S., Abebaw, A., Getachew, M., & Jin, T. (2021) · Seminars in Immunology · doi:10.1016/j.smim.2021.101533 · Cited by 115
A Review on SERS-Based Detection of Human Virus Infections: Influenza and Coronavirus
Saviñon-Flores, F., Méndez, E., López-Castaños, M., Carabarín‐Lima, A., López-Castaños, K. A., González‐Fuentes, M. A., & Méndez‐Albores, A. (2021) · Biosensors · doi:10.3390/bios11030066 · Cited by 117
Differential effects of the second SARS-CoV-2 mRNA vaccine dose on T cell immunity in naive and COVID-19 recovered individuals
Lozano‐Ojalvo, D., Cámara, C., López‐Granados, E., Nozal, P., Molina, L. D. P., Bravo‐Gallego, L. Y., Paz‐Artal, E., Pion, M., Correa‐Rocha, R., Ortíz, A., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.109570 · Cited by 109
mRNA vaccines for COVID-19 and diverse diseases
Hussain, A., Yang, H., Zhang, M., Liu, Q., Alotaibi, G., Irfan, M. F., He, H., Chang, J. K., Liang, X., Weng, Y., et al. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.03.032 · Cited by 121
A Newcastle disease virus expressing a stabilized spike protein of SARS-CoV-2 induces protective immune responses
Sun, W., Liu, Y., Amanat, F., González‐Domínguez, I., McCroskery, S., Slamanig, S., Coughlan, L., Rosado, V. C., Lemus, N., Jangra, S., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-26499-y · Cited by 108
Self-citation
Intranasal vaccination with lipid-conjugated immunogens promotes antigen transmucosal uptake to drive mucosal and systemic immunity
Hartwell, B. L., Melo, M. B., Xiao, P., Lemnios, A. A., Li, N., Chang, J. Y. H., Yu, J., Gebre, M. S., Chang, A., Maiorino, L., et al. (2022) · Science Translational Medicine · doi:10.1126/scitranslmed.abn1413 · Cited by 112
T cell immunity to SARS-CoV-2 following natural infection and vaccination
DiPiazza, A. T., Graham, B. S., & Ruckwardt, T. J. (2020) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2020.10.060 · Cited by 109
Recent advances in carbon quantum dots for virus detection, as well as inhibition and treatment of viral infection
Xue, Y., Liu, C., Andrews, G., Wang, J., & Ge, Y. (2022) · Nano Convergence · doi:10.1186/s40580-022-00307-9 · Cited by 114
Immunogenicity and crossreactivity of antibodies to the nucleocapsid protein of SARS-CoV-2: utility and limitations in seroprevalence and immunity studies
Dobaño, C., Santano, R., Jiménez, A., Vidal, M., Chi, J., Melero, N. R., Popovic, M., López-Aladid, R., Fernández‐Barat, L., Tortajada, M., et al. (2021) · Translational research · doi:10.1016/j.trsl.2021.02.006 · Cited by 110
Fast and noninvasive electronic nose for sniffing out COVID-19 based on exhaled breath-print recognition
Nurputra, D. K., Kusumaatmaja, A., Hakim, M. S., Hidayat, S. N., Julian, T., Sumanto, B., Mahendradhata, Y., Saktiawati, A. M. I., Wasisto, H. S., & Trıyana, K. (2022) · npj Digital Medicine · doi:10.1038/s41746-022-00661-2 · Cited by 111
Immunological memory to SARS-CoV-2 assessed for up to eight months after infection.
Dan, J. M., Mateus, J., Kato, Y., Hastie, K. M., Yu, E. D., Faliti, C. E., Grifoni, A., Ramirez, S. I., Haupt, S., Frazier, A., et al. (2020) · eScholarship (California Digital Library) · Cited by 121
Self-citation
Immunogenicity of clinically relevant SARS-CoV-2 vaccines in nonhuman primates and humans
Klasse, P. J., Nixon, D. F., & Moore, J. P. (2021) · Science Advances · doi:10.1126/sciadv.abe8065 · Cited by 104
Immunogenicity and protective efficacy of inactivated SARS-CoV-2 vaccine candidate, BBV152 in rhesus macaques
Yadav, P. D., Ella, R., Kumar, S., Patil, D., Mohandas, S., Shete, A. M., Vadrevu, K. M., Bhati, G., Sapkal, G. N., Kaushal, H., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-21639-w · Cited by 105
Sex Differences in Respiratory Viral Pathogenesis and Treatments
Ursin, R. L., & Klein, S. L. (2021) · Annual Review of Virology · doi:10.1146/annurev-virology-091919-092720 · Cited by 109
Convergent antibody responses to the SARS-CoV-2 spike protein in convalescent and vaccinated individuals
Chen, E. C., Gilchuk, P., Zost, S. J., Suryadevara, N., Winkler, E. S., Cabel, C. R., Binshtein, E., Chen, R. E., Sutton, R. E., Rodriguez, J. L., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.109604 · Cited by 102
The potential neurological effect of the COVID‐19 vaccines: A review
Lu, L., Xiong, W., Mu, J., Zhang, Q., Zhang, H., Zou, L., Li, W., He, L., Sander, J. W. A. S., & Zhou, D. (2021) · Acta Neurologica Scandinavica · doi:10.1111/ane.13417 · Cited by 104
Peptides for Vaccine Development
Hamley, I. W. (2022) · ACS Applied Bio Materials · doi:10.1021/acsabm.1c01238 · Cited by 104
Impact of the Use of Oral Antiviral Agents on the Risk of Hospitalization in Community Coronavirus Disease 2019 Patients (COVID-19)
Yip, T. C., Lui, G. C.-Y., Lai, M. S., Wong, V. W., Tse, Y. K., Ma, B. H.-M., Hui, E., Leung, M. K., Chan, H. L., Hui, D. S.-C., et al. (2022) · Clinical Infectious Diseases · doi:10.1093/cid/ciac687 · Cited by 98
Recent Advances in Covalent Drug Discovery
Schaefer, D., & Cheng, X. (2023) · Pharmaceuticals · doi:10.3390/ph16050663 · Cited by 117
Robust SARS-CoV-2 Infection in Nasal Turbinate Despite Systemic Neutralizing Antibody
Zhou, D., Chan, J. F., Zhou, B., Zhou, R., Li, S., Shan, S., Liu, L., Zhang, J., Chen, S. J., Chan, C. C., et al. (2020) · Cell Host & Microbe · doi:10.1016/j.chom.2021.02.019 · Cited by 101
Virus vaccines: proteins prefer prolines
Sanders, R. W., & Moore, J. P. (2021) · Cell Host & Microbe · doi:10.1016/j.chom.2021.02.002 · Cited by 97
An antiviral trap made of protein nanofibrils and iron oxyhydroxide nanoparticles
Palika, A., Armanious, A., Rahimi, A., Medaglia, C., Gasbarri, M., Handschin, S., Rossi, A. M., Pohl, M. O., Busnadiego, I., Gübeli, C., et al. (2021) · Nature Nanotechnology · doi:10.1038/s41565-021-00920-5 · Cited by 101
Nanoparticle-Mediated Cytoplasmic Delivery of Messenger RNA Vaccines: Challenges and Future Perspectives
Wu, Z., & Li, T. (2021) · Pharmaceutical Research · doi:10.1007/s11095-021-03015-x · Cited by 103
Targeting the Conserved Stem Loop 2 Motif in the SARS-CoV-2 Genome
Lulla, V., Wandel, M. P., Bandyra, K. J., Ulferts, R., Wu, M., Dendooven, T., Yang, X., Doyle, N., Oerum, S., Beale, R. C. L., et al. (2021) · Journal of Virology · doi:10.1128/jvi.00663-21 · Cited by 101
Emergence of immune escape at dominant SARS-CoV-2 killer T cell epitope
Dolton, G. M., Rius, C., Hasan, M. S., Wall, A., Szomolay, B., Behiry, E. M., Whalley, T., Southgate, J., Fuller, A., Morin, T., et al. (2022) · Cell · doi:10.1016/j.cell.2022.07.002 · Cited by 100
An overview on nanoparticle-based strategies to fight viral infections with a focus on COVID-19
Yasamineh, S., Kalajahi, H. G., Yasamineh, P., Yazdani, Y., Gholizadeh, O., Tabatabaie, R., Afkhami, H., Davodabadi, F., farkhad, A. K., Pahlevan, D., et al. (2022) · Journal of Nanobiotechnology · doi:10.1186/s12951-022-01625-0 · Cited by 102
Structural and non-structural proteins in SARS-CoV-2: potential aspects to COVID-19 treatment or prevention of progression of related diseases
Kakavandi, S., Zare, I., Vaezjalali, M., Dadashi, M., Azarian, M., Akbari, A., Farani, M. R., Zalpoor, H., & Hajikhani, B. (2023) · Cell Communication and Signaling · doi:10.1186/s12964-023-01104-5 · Cited by 110
The Promising Potential of Reverse Vaccinology-Based Next-Generation Vaccine Development over Conventional Vaccines against Antibiotic-Resistant Bacteria
Khalid, K., & Poh, C. L. (2023) · Vaccines · doi:10.3390/vaccines11071264 · Cited by 106
Intranasal mRNA-LNP vaccination protects hamsters from SARS-CoV-2 infection
Vaca, G. B., Meyer, M., Cadete, A., Hsiao, C. J., Golding, A. S., Jeon, A. B., Jacquinet, E., Azcue, E., Guan, C. M., Sanchez-Felix, X., et al. (2023) · Science Advances · doi:10.1126/sciadv.adh1655 · Cited by 101
A TLR7-nanoparticle adjuvant promotes a broad immune response against heterologous strains of influenza and SARS-CoV-2
Yin, Q., Luo, W., Mallajosyula, V. V. A., Yang, B., Guo, J., Xie, J., Sun, M., Verma, R., Li, C., Constantz, C. M., et al. (2023) · Nature Materials · doi:10.1038/s41563-022-01464-2 · Cited by 100
Anticipation of COVID-19 vaccines reduces willingness to socially distance
Andersson, O., Campos-Mercade, P., Meier, A. N., & Wengström, E. (2021) · Journal of Health Economics · doi:10.1016/j.jhealeco.2021.102530 · Cited by 97
Current and future nanoparticle vaccines for COVID-19
Vu, M. N., Kelly, H. G., Kent, S. J., & Wheatley, A. K. (2021) · EBioMedicine · doi:10.1016/j.ebiom.2021.103699 · Cited by 101
Bacterial membrane vesicles for vaccine applications
Krishnan, N., Kubiatowicz, L. J., Holay, M., Zhou, J., Fang, R. H., & Zhang, L. (2022) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2022.114294 · Cited by 97
SARS-CoV-2 Vaccines, Vaccine Development Technologies, and Significant Efforts in Vaccine Development during the Pandemic: The Lessons Learned Might Help to Fight against the Next Pandemic
Chakraborty, C., Bhattacharya, M., & Dhama, K. (2023) · Vaccines · doi:10.3390/vaccines11030682 · Cited by 112
Asymptomatic and symptomatic SARS-CoV-2 infections elicit polyfunctional antibodies
Dufloo, J., Grzelak, L., Staropoli, I., Madec, Y., Tondeur, L., Anna, F., Pelleau, S., Wiedemann, A., Planchais, C., Buchrieser, J., et al. (2021) · Cell Reports Medicine · doi:10.1016/j.xcrm.2021.100275 · Cited by 89
Evidence for adaptive evolution in the receptor-binding domain of seasonal coronaviruses OC43 and 229e
Kistler, K. E., & Bedford, T. (2021) · eLife · doi:10.7554/elife.64509 · Cited by 94
Vaccinology in the post−COVID-19 era
Rappuoli, R., Gregorio, E. D., Giudice, G. D., Phogat, S. K., Pecetta, S., Pizza, M., & Hanon, E. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2020368118 · Cited by 95
COVID-19 pandemics Stage II – Energy and environmental impacts of vaccination
Klemeš, J. J., Jiang, P., Fan, Y. V., Bokhari, A., & Wang, X. (2021) · Renewable and Sustainable Energy Reviews · doi:10.1016/j.rser.2021.111400 · Cited by 99
Safety and efficacy of COVID‐19 vaccines: A systematic review and meta‐analysis of controlled and randomized clinical trials
Beladiya, J., Kumar, A., Vasava, Y., Parmar, K., Patel, D., Patel, S., Dholakia, S., Sheth, D., Boddu, S. H. S., & Patel, C. (2024) · Reviews in Medical Virology · doi:10.1002/rmv.2507 · Cited by 96
Gold-Nanostar-Chitosan-Mediated Delivery of SARS-CoV‑2 DNA Vaccine for Respiratory Mucosal Immunization: Development and Proof-of-Principle
Sukumar, U. K., Afjei, R., Ferrara, K. W., Massoud, T. F., & Paulmurugan, R. (2021) · ACS Nano · doi:10.1021/acsnano.1c05002 · Cited by 95
SARS-CoV-2 infection and viral fusogens cause neuronal and glial fusion that compromises neuronal activity
Martínez-Mármol, R., Giordano-Santini, R., Kaulich, E., Cho, A.-N., Przybyla, M., Riyadh, M. A., Robinson, E., Chew, K. Y., Amor, R., Meunier, F. A., et al. (2023) · Science Advances · doi:10.1126/sciadv.adg2248 · Cited by 94
Structural analysis of receptor binding domain mutations in SARS-CoV-2 variants of concern that modulate ACE2 and antibody binding
Mannar, D., Saville, J. W., Zhu, X. Q., Srivastava, S. S., Berezuk, A., Zhou, S., Tuttle, K. S., Kim, A., Li, W., Dimitrov, D. S., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.110156 · Cited by 90
Immunogenicity and efficacy of the COVID-19 candidate vector vaccine MVA-SARS-2-S in preclinical vaccination
Tscherne, A., Schwarz, J. H., Rohde, C., Kupke, A., Kalodimou, G., Limpinsel, L., Okba, N. M. A., Bošnjak, B., Sandrock, I., Odak, I., et al. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2026207118 · Cited by 91
Inhaled vaccine delivery in the combat against respiratory viruses: a 2021 overview of recent developments and implications for COVID-19
Heida, R., Hinrichs, W. L. J., & Frijlink, H. W. (2021) · Expert Review of Vaccines · doi:10.1080/14760584.2021.1903878 · Cited by 96
Mutation-induced Changes in the Receptor-binding Interface of the SARS-CoV-2 Delta Variant B.1.617.2 and Implications for Immune Evasion
Baral, P., Bhattarai, N., Hossen, M. L., Stebliankin, V., Gerstman, B. S., Narasimhan, G., & Chapagain, P. P. (2021) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2021.08.036 · Cited by 94
Bi-objective optimization for a multi-period COVID-19 vaccination planning problem
Tang, L., Li, Y., Bai, D., Liu, T., & Coelho, L. C. (2022) · Omega · doi:10.1016/j.omega.2022.102617 · Cited by 92
Effectiveness of SARS-CoV-2 Vaccination in a Veterans Affairs Cohort of Patients With Inflammatory Bowel Disease With Diverse Exposure to Immunosuppressive Medications
Khan, N. H., & Mahmud, N. (2021) · Gastroenterology · doi:10.1053/j.gastro.2021.05.044 · Cited by 91
SARS-CoV-2 vaccines in advanced clinical trials: Where do we stand?
Chakraborty, S., Mallajosyula, V. V. A., Tato, C. M., Tan, G. S., & Wang, T. T. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.01.014 · Cited by 90
The success of SARS-CoV-2 vaccines and challenges ahead
Subbarao, K. (2021) · Cell Host & Microbe · doi:10.1016/j.chom.2021.06.016 · Cited by 92
Potent Anti-SARS-CoV-2 Activity by the Natural Product Gallinamide A and Analogues via Inhibition of Cathepsin L
Ashhurst, A. S., Tang, A. H., Fajtová, P., Yoon, M. C., Aggarwal, A., Bedding, M. J., Stoye, A., Beretta, L., Pwee, D., Drelich, A. K., et al. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c01494 · Cited by 95
mRNA vaccines against SARS-CoV-2 induce comparably low long-term IgG Fc galactosylation and sialylation levels but increasing long-term IgG4 responses compared to an adenovirus-based vaccine
Buhre, J. S., Pongrácz, T., Künsting, I., Lixenfeld, A. S., Wang, W., Nouta, J., Lehrian, S., Schmelter, F., Lunding, H. B., Dühring, L., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1020844 · Cited by 90
Strong immune responses and protection of PcrV and OprF-I mRNA vaccine candidates against Pseudomonas aeruginosa
Wang, X., Liu, C., Rcheulishvili, N., Papukashvili, D., Xie, F., Zhao, J., Hu, X., Yu, K., Yang, N., Pan, X., et al. (2023) · npj Vaccines · doi:10.1038/s41541-023-00672-4 · Cited by 94
A modified vaccinia Ankara vector-based vaccine protects macaques from SARS-CoV-2 infection, immune pathology, and dysfunction in the lungs
Routhu, N. K., Cheedarla, N., Gangadhara, S., Bollimpelli, V. S., Boddapati, A. K., Shiferaw, A., Rahman, S. A., Sahoo, A., Edara, V. V., Lai, L., et al. (2021) · Immunity · doi:10.1016/j.immuni.2021.02.001 · Cited by 85
AHR signaling is induced by infection with coronaviruses
Giovannoni, F., Li, Z., Lenicov, F. R., Dávola, M. E., Elizalde, M. M., Paletta, A. L., Ashkar, A. A., Mossman, K. L., Dugour, A. V., Figueroa, J. M., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-25412-x · Cited by 90
Human coronaviruses: Origin, host and receptor
Tang, G., Liu, Z., & Chen, D. (2022) · Journal of Clinical Virology · doi:10.1016/j.jcv.2022.105246 · Cited by 98
SARS-CoV-2 and innate immunity: the good, the bad, and the “goldilocks”
Sievers, B. L., Cheng, M. T. K., Csiba, K., Meng, B., & Gupta, R. K. (2023) · Cellular and Molecular Immunology · doi:10.1038/s41423-023-01104-y · Cited by 91
Declining Levels of Neutralizing Antibodies Against SARS-CoV-2 in Convalescent COVID-19 Patients One Year Post Symptom Onset
Xiang, T., Liang, B., Fang, Y., Lu, S., Li, S., Wang, H., Li, H., Yang, X., Shěn, S., Zhu, B., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.708523 · Cited by 84
SARS-CoV-2 RBD-Tetanus Toxoid Conjugate Vaccine Induces a Strong Neutralizing Immunity in Preclinical Studies
Valdés-Balbín, Y., Santana-Mederos, D., Quintero, L., Fernández-Castillo, S., Rodríguez, L., Ramírez, B. S., Pérez-Nicado, R., Acosta, C., Méndez, Y., Ricardo, M. G., et al. (2021) · ACS Chemical Biology · doi:10.1021/acschembio.1c00272 · Cited by 85
Small‐Molecule Quenchers for Förster Resonance Energy Transfer: Structure, Mechanism, and Applications
Fang, B., Shen, Y., Peng, B., Bai, H., Wang, L., Zhang, J., Hu, W., Fu, L., Zhang, W., Li, L., et al. (2022) · Angewandte Chemie International Edition · doi:10.1002/anie.202207188 · Cited by 86
A structural view of the SARS-CoV-2 virus and its assembly
Hardenbrook, N. J., & Zhang, P. (2021) · Current Opinion in Virology · doi:10.1016/j.coviro.2021.11.011 · Cited by 93
A Systematic Review on COVID-19 Vaccine Strategies, Their Effectiveness, and Issues
Khandker, S. S., Godman, B., Jawad, M. I., Meghla, B. A., Tisha, T. A., Khondoker, M. U., Haq, M. A., Charan, J., Talukder, A. A., Azmuda, N., et al. (2021) · Vaccines · doi:10.3390/vaccines9121387 · Cited by 88
Vaccine Side Effects Following COVID-19 Vaccination Among the Residents of the UAE—An Observational Study
Ganesan, S., AlKetbi, L. B., Kaabi, N. A. M. A., Mansoori, M. A., Maskari, N. N. A., AlShamsi, M. S., Alderei, A. S., Eissaee, H. N. E., AlKetbi, R. M., AlShamsi, N., et al. (2022) · Frontiers in Public Health · doi:10.3389/fpubh.2022.876336 · Cited by 87
An imidazole modified lipid confers enhanced mRNA-LNP stability and strong immunization properties in mice and non-human primates
Ripoll, M., Bernard, M., Vaure, C., Bazin, E., Commandeur, S., Perkov, V., Lemdani, K., Nicolaï, M., Bonifassi, P., Kichler, A., et al. (2022) · Biomaterials · doi:10.1016/j.biomaterials.2022.121570 · Cited by 89
Vaccines for COVID-19 - state of the art
Lima, E. J. D. F., Almeida, A. M., & Kfouri, R. D. Á. (2021) · Revista Brasileira de Saúde Materno Infantil · doi:10.1590/1806-9304202100s100002 · Cited by 96
Introduction of Two Prolines and Removal of the Polybasic Cleavage Site Lead to Higher Efficacy of a Recombinant Spike-Based SARS-CoV-2 Vaccine in the Mouse Model
Amanat, F., Strohmeier, S., Rathnasinghe, R., Schotsaert, M., Coughlan, L., García‐Sastre, A., & Krammer, F. (2021) · mBio · doi:10.1128/mbio.02648-20 · Cited by 86
Self-citation
Inhalable nanovaccine with biomimetic coronavirus structure to trigger mucosal immunity of respiratory tract against COVID-19
Zheng, B., Peng, W., Guo, M., Huang, M., Gu, Y., Wang, T., Ni, G., & Ming, D. (2021) · Chemical Engineering Journal · doi:10.1016/j.cej.2021.129392 · Cited by 83
A recombinant spike protein subunit vaccine confers protective immunity against SARS-CoV-2 infection and transmission in hamsters
Wu, Y., Huang, X., Yuan, L., Wang, S., Zhang, Y., Xiong, H., Chen, R., Ma, J., Qi, R., Nie, M., et al. (2021) · Science Translational Medicine · doi:10.1126/scitranslmed.abg1143 · Cited by 82
Sequence signatures of two public antibody clonotypes that bind SARS-CoV-2 receptor binding domain
Tan, T. J. C., Yuan, M., Kuzelka, K., Padron, G. C., Beal, J. R., Chen, X., Wang, Y., Rivera-Cardona, J., Zhu, X., Stadtmueller, B. M., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-24123-7 · Cited by 75
E484K mutation in SARS-CoV-2 RBD enhances binding affinity with hACE2 but reduces interactions with neutralizing antibodies and nanobodies: Binding free energy calculation studies
Wang, W. B., Liang, Y., Jin, Y. Q., Zhang, J., Su, J. G., & Li, Q. M. (2021) · Journal of Molecular Graphics and Modelling · doi:10.1016/j.jmgm.2021.108035 · Cited by 83
Contribution of single mutations to selected SARS-CoV-2 emerging variants spike antigenicity
Gong, S. Y., Chatterjee, D., Richard, J., Prévost, J., Tauzin, A., Gasser, R., Bo, Y., Vézina, D., Goyette, G., Gendron‐Lepage, G., et al. (2021) · Virology · doi:10.1016/j.virol.2021.09.001 · Cited by 81
Clinical development and approval of COVID-19 vaccines
Kalinke, U., Barouch, D. H., Rizzi, R., Lagkadinou, E., Türeci, Ö., Pather, S., & Neels, P. (2022) · Expert Review of Vaccines · doi:10.1080/14760584.2022.2042257 · Cited by 86
COVID-19 mRNA booster vaccine induces transient CD8+ T effector cell responses while conserving the memory pool for subsequent reactivation
Reinscheid, M., Luxenburger, H., Karl, V., Graeser, A., Giese, S., Ciminski, K., Reeg, D. B., Oberhardt, V., Roehlen, N., Lang‐Meli, J., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-32324-x · Cited by 79
Vaccine formulations in clinical development for the prevention of severe acute respiratory syndrome coronavirus 2 infection
Batty, C. J., Heise, M. T., Bachelder, E. M., & Ainslie, K. M. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.12.006 · Cited by 86
Berberine and Obatoclax Inhibit SARS-Cov-2 Replication in Primary Human Nasal Epithelial Cells In Vitro
Varghese, F. S., van Woudenbergh, E., Overheul, G. J., Eleveld, M. J., Kurver, L., van Heerbeek, N., van Laarhoven, A., Miesen, P., den Hartog, G., de Jonge, M. I., et al. (2021) · Viruses · doi:10.3390/v13020282 · Cited by 80
Emerging SARS-CoV-2 Variants: Genetic Variability and Clinical Implications
Dubey, A., Choudhary, S., Kumar, P., & Tomar, S. (2021) · Current Microbiology · doi:10.1007/s00284-021-02724-1 · Cited by 79
The mechanism underlying extrapulmonary complications of the coronavirus disease 2019 and its therapeutic implication
Ning, Q., Wu, D., Wang, X., Xi, D., Chen, T., Chen, G., Wang, H., Lü, H., Wang, M., Zhu, L., et al. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-00907-1 · Cited by 86
Immunological surrogate endpoints of COVID-2019 vaccines: the evidence we have versus the evidence we need
Jin, P., Li, J., Pan, H., Wu, Y., & Zhu, F. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00481-y · Cited by 80
Development and deployment of COVID-19 vaccines for those most vulnerable
Koff, W. C., Schenkelberg, T., Williams, T. M., Baric, R. S., McDermott, A. B., Cameron, C., Cameron, M. J., Frieman, M. B., Neumann, G., Kawaoka, Y., et al. (2021) · Science Translational Medicine · doi:10.1126/scitranslmed.abd1525 · Cited by 80
Membrane cofactor protein (MCP; CD46): deficiency states and pathogen connections
Liszewski, M. K., & Atkinson, J. P. (2021) · Current Opinion in Immunology · doi:10.1016/j.coi.2021.04.005 · Cited by 80

Authors: Krammer, F.
Affiliations: Icahn School of Medicine at Mount Sinai (US)
Corresponding author: Krammer, Florian
ORCID: Krammer, Florian
Venue: Nature
Publisher: Springer Science and Business Media LLC
Published: 2020-09-23
Volume: 586
Issue: 7830
Pages: 516-527
ISSN: 0028-0836 (ISSN-L)
1476-4687
DOI: 10.1038/s41586-020-2798-3
OpenAlex: W3087924281
Cited by: 2,098
References: 101
Citations by year: 2026: 91 · 2025: 147 · 2024: 173 · 2023: 287 · 2022: 538 · 2021: 747 · 2020: 112
FWCI: 19.97
Type: journal article
Language: en
Open access: green
doi.org
Licence: cc-by
www.springer.com/tdm (tdm)
www.springer.com/tdm (vor)
Locations: Nature (publishedVersion)
PubMed (publishedVersion)
RePEc: Research Papers in Economics (submittedVersion)
Zenodo (CERN European Organization for Nuclear Research) (cc-by)
Funders: JPB Foundation (2020-215611, HHSN272201400008C, 75N93019C00051)
Open Philanthropy Project (#2020-215611, 75N93019C00051, HHSN272201400008C)
National Institute of Allergy and Infectious Diseases (HHSN272201400008C), 75N93019C00051, 2020-215611, HHSN272201800048C)
Topics: Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
Life Sciences › Agricultural and Biological Sciences › Animal Science and Zoology › Animal Virus Infections Studies
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › vaccines and immunoinformatics approaches
Keywords: SARS-CoV-2, COVID-19 vaccines, vaccine development, vaccine candidate, clinical trials, animal studies, vaccine safety, vaccine efficacy, COVID-19 pandemic
MeSH terms: Drug Development, COVID-19, COVID-19 Vaccines, Animals, Clinical Trials as Topic, Drug Industry, Humans, Pneumonia, Viral, Viral Vaccines, Coronavirus Infections, Immunity, Mucosal, Pandemics

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

SARS-CoV-2 vaccines in development

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks